CSIMarket
 


Ionis Pharmaceuticals Inc   (IONS)
Other Ticker:  
 
 

IONS's Revenue Growth by Quarter and Year

Ionis Pharmaceuticals Inc 's Revenue results by quarter and year




IONS Revenue (in millions $) FY 2024 FY 2023 FY 2022 FY 2021
IV Quarter December - 379.13 133.79 125.75
III Quarter September - 144.21 141.92 111.61
II Quarter June - 130.52 440.01 290.28
I Quarter March 119.50 178.56 133.09 160.08
FY   119.50 832.42 848.81 687.72



IONS Revenue first quarter 2024 Y/Y Growth Comment
Ionis Pharmaceuticals Inc reported fall in Revenue in the first quarter 2024 by -33.08% to $ 119.50 millions, from the same quarter in 2023.
The drop in the first quarter 2024 Ionis Pharmaceuticals Inc 's Revenue compares unfavorably to the Company's average Revenue rise of 27.73%.

Looking into first quarter 2024 results within Major Pharmaceutical Preparations industry 72 other companies have achieved higher Revenue growth. While Ionis Pharmaceuticals Inc ' s Revenue drop of -33.08% ranks overall at the positon no. 1035 in the first quarter 2024.




IONS Revenue ( Y/Y Growth %) 2024
2023 2022 2021
IV Quarter December - 183.38 % 6.39 % -13.6 %
III Quarter September - 1.61 % 27.16 % -16.32 %
II Quarter June - -70.34 % 51.58 % -41.2 %
I Quarter March -33.08 % 34.16 % -16.86 % -4.65 %
FY   - -1.93 % 23.42 % -26.88 %

Financial Statements
Ionis Pharmaceuticals Inc 's first quarter 2024 Revenue $ 119.50 millions IONS's Income Statement
Ionis Pharmaceuticals Inc 's first quarter 2023 Revenue $ 178.56 millions Quarterly IONS's Income Statement
New: More IONS's historic Revenue Growth >>


IONS Revenue (Quarter on Quarter Growth %)

2024
2023 2022 2021
IV Quarter December - 162.9 % -5.73 % 12.67 %
III Quarter September - 10.49 % -67.75 % -61.55 %
II Quarter June - -26.9 % 230.61 % 81.33 %
I Quarter March -68.48 % 33.46 % 5.84 % 9.99 %
FY (Year on Year)   - -1.93 % 23.42 % -26.88 %




Revenue first quarter 2024 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #73
Healthcare Sector #192
Overall #1035

Revenue Y/Y Growth Statistics
High Average Low
175.93 % 27.73 % -43.57 %
(Jun 30 2017)   (June 30. 2016)
Revenue first quarter 2024 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #73
Healthcare Sector #192
Overall #1035
Revenue Y/Y Growth Statistics
High Average Low
175.93 % 27.73 % -43.57 %
(Jun 30 2017)   (June 30. 2016)

Revenue by Quarter for the Fiscal Years 2021, 2022, 2023, 2024

Ionis Pharmaceuticals Inc 's Q/Q Revenue Growth


Revenue Q/Q Growth Statistics
High Average Low
230.6 % 25.35 % -75.49 %
(Dec 31 2021)  


IONS's I. Quarter Q/Q Revenue Comment
In the I. Quarter 2024 Ionis Pharmaceuticals Inc reported fall in Revenue from the fourth quarter by -68.48% to $ 119.50 millions, from $ 379.13 millions declared in the previous quarter.

Although cyclical factors usually energize I. Quarter 2024 results, it plainly was not substantial to salvage Major Pharmaceutical Preparations's company achievement, Elijah Wright, market expert allocated in San Francisco wrote.

Within Major Pharmaceutical Preparations industry 120 other companies have achieved higher Revenue quarter on quarter growth. While Ionis Pharmaceuticals Inc 's Revenue growth quarter on quarter, overall rank is 2424.


Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #121
Healthcare Sector #332
Overall #2424
Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #121
Healthcare Sector #332
Overall #2424
Revenue Q/Q Growth Statistics
High Average Low
230.6 % 25.35 % -75.49 %
(Dec 31 2021)  


IONS's I. Quarter Q/Q Revenue Comment
In the I. Quarter 2024 Ionis Pharmaceuticals Inc reported fall in Revenue from the fourth quarter by -68.48% to $ 119.50 millions, from $ 379.13 millions declared in the previous quarter.

Even cyclical influence which commonly energize I. Quarter 2024 performance, it simply could not be enough to salvage IONS's I. Quarter performance, Elijah Wright, market expert allocated in San Francisco said and continued that average quarter on quarter Revenue growth is at 25.35% for Ionis Pharmaceuticals Inc .

Within Major Pharmaceutical Preparations industry 120 other companies have achieved higher Revenue quarter on quarter growth. While Ionis Pharmaceuticals Inc 's Revenue growth quarter on quarter, overall rank is 2424.


Ionis Pharmaceuticals Inc 's 12 Months Revenue Growth Year on Year


Revenue TTM Growth

12 Months Ending
(Mar 31 2024)
12 Months Ending
(Dec 31 2023)
12 Months Ending
(Sep 30 2023)
12 Months Ending
(Mar 31 2023)
12 Months Ending
(Dec 31 2022)
Cumulative Revenue 12 Months Ending $ 773.35 $ 832.42 $ 587.09 $ 584.80 $ 894.28
Y / Y Revenue Growth (TTM) -13.52 % -1.93 % -30.17 % -27.84 % 35.35 %
Year on Year Revenue Growth Overall Ranking # 216 # 476 # 624 # 447 # 2217
Seqeuential Revenue Change (TTM) -7.1 % 41.79 % 0.39 % -34.61 % 5.36 %
Seq. Revenue Growth (TTM) Overall Ranking # 1035 # 1637 # 1395 # 212 # 2870




Cumulative Revenue growth Comment
Ionis Pharmaceuticals Inc 's cumulative 12 months Revenue continue to fall, but on the faster rate at -13.52% year on year, at Mar 31 2024 compare to the -1.93% decrease at Dec 31 2023. If the Ionis Pharmaceuticals Inc 's fiscal year would end at Mar 31 2024, annual Revenue would be $773 millions.

In the Healthcare sector 61 other companies have achieved higher trailing twelve month Revenue growth. While Total ranking has impoved so far to 216, from total ranking in previous quarter at 476.

Revenue TTM Q/Q Growth Statistics
High Average Low
175.93 %
27.73 %
-43.57 %
 

Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 73
Healthcare Sector # 62
Overall # 216

Revenue TTM Y/Y Growth Statistics
High Average Low
175.93 %
27.73 %
-43.57 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 73
Sector # 192
S&P 500 # 1035
Cumulative Revenue growth Comment
Ionis Pharmaceuticals Inc 's cumulative 12 months Revenue continue to fall, but on the faster rate at -13.52% year on year, at Mar 31 2024 compare to the -1.93% decrease at Dec 31 2023. If the Ionis Pharmaceuticals Inc 's fiscal year would end at Mar 31 2024, annual Revenue would be $773 millions.

In the Healthcare sector 61 other companies have achieved higher trailing twelve month Revenue growth. While Total ranking has impoved so far to 216, from total ranking in previous quarter at 476.

Revenue TTM Q/Q Growth Statistics
High Average Low
175.93 %
27.73 %
-43.57 %
 


Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 73
Healthcare Sector # 62
Overall # 216

Revenue TTM Y/Y Growth Statistics
High Average Low
175.93 %
27.73 %
-43.57 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 73
Sector # 192
S&P 500 # 1035




Other Revenue Growth
Major Pharmaceutical Preparations Industry Revenue Growth Trends and Statistics
Healthcare Sector Revenue Growth Statistics
Revenue Growth Trends for overall market
IONS's Revenue Growth Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Revenue Growth
Lowest Ranking Revenue Growth
Revenue Growth for IONS's Competitors
Revenue Growth for Ionis Pharmaceuticals Inc 's Suppliers
Revenue Growth for IONS's Customers

You may also want to know
IONS's Annual Growth Rates IONS's Profitability Ratios IONS's Asset Turnover Ratio IONS's Dividend Growth
IONS's Roe IONS's Valuation Ratios IONS's Financial Strength Ratios IONS's Dividend Payout Ratio
IONS's Roa IONS's Inventory Turnover Ratio IONS's Growth Rates IONS's Dividend Comparisons



Companies with similar Revenue fall for the quarter ending Mar 31 2024 within Healthcare SectorY/Y Change %Revenue for the quarter ending Mar 31 2024
Collegium Pharmaceutical inc -0.21%$ -0.215 millions
Mettler Toledo International Inc-0.30%$ -0.300 millions
3m Company-0.35%$ -0.349 millions
Icu Medical Inc-0.42%$ -0.423 millions
Lifeloc Technologies Inc -0.51%$ -0.513 millions
Regeneron Pharmaceuticals Inc -0.54%$ -0.541 millions
Envista Holdings Corporation-0.62%$ -0.622 millions
Orgenesis Inc -0.70%$ -0.704 millions
Vyne Therapeutics Inc -1.01%$ -1.010 millions
Ge Healthcare Technologies Inc -1.50%$ -1.502 millions
Baxter International Inc -1.56%$ -1.562 millions
Y mabs Therapeutics inc -1.58%$ -1.580 millions
Pacific Biosciences Of California Inc -1.59%$ -1.589 millions
Cartesian Therapeutics Inc -1.65%$ -1.650 millions
Viatris Inc -1.76%$ -1.762 millions
Ocuphire Pharma Inc -2.17%$ -2.173 millions
Vaso Corporation-2.51%$ -2.513 millions
Dentsply Sirona Inc -2.56%$ -2.556 millions
Alpha Pro Tech Ltd -2.78%$ -2.775 millions
Prestige Consumer Healthcare Inc -2.82%$ -2.817 millions
West Pharmaceutical Services Inc -2.99%$ -2.986 millions
Integra Lifesciences Holdings Corp-3.14%$ -3.144 millions
Accelerate Diagnostics Inc -3.17%$ -3.165 millions
National Research Corporation-3.18%$ -3.180 millions
Catheter Precision Inc -3.53%$ -3.529 millions
Elanco Animal Health Inc-4.14%$ -4.137 millions
Ptc Therapeutics inc -4.66%$ -4.657 millions
Foghorn Therapeutics Inc -4.88%$ -4.879 millions
Aclaris Therapeutics Inc -5.14%$ -5.142 millions
Avantor Inc -5.65%$ -5.645 millions




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com